BofA Raises Merck (MRK) Price Target to $105, Keeps Buy Rating

Core Insights - Merck & Co., Inc. (NYSE:MRK) is recognized as one of the 15 Best Stocks to Buy for the Medium Term [1] - BofA analyst Tim Anderson raised the price target for Merck to $105 from $98 while maintaining a Buy rating, highlighting the potential of the Cidara deal and its alignment with Merck's Infectious Disease franchise [2] - In Q3 2025, Merck reported revenue of $17.3 billion, a 4% increase year-over-year, with KEYTRUDA sales growing 10% to $8.1 billion, and expects total revenue to reach between $64.5 billion and $65 billion [3] - New product approvals contributed to growth, with Winrevair generating $360 million in Q3 and Capvaxive reporting $244 million in sales, alongside a strong pipeline of over 80 active clinical trials [4] - The animal health segment also saw a 9% year-over-year sales increase to $1.6 billion, driven by rising pet-related spending [5]